MAP Pharma (MAPP) Misses Q4 Views by 2c
- Top 10 News for 12/15 - 12/19: Russia Raises Rates, Ruble Retreats; U.S., Cuba Get Friendly; Sony Crumbles Under Pressure
- BlackBerry (BBRY) Posts Surprise Q3 Profit; Reports 100% Sequential Growth in BES10 Licenses
- Facebook's (FB) Instagram is Bigger and Better than Twitter (TWTR), Should Be Worth $35 Billion - Citi
- Nike (NKE) Tops Q2 EPS by 4c; Adjusted Futures Orders Rose 11%
- Fed's Williams Says June Good Time to Consider 'Lift-Off'
MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) reported Q4 loss of $0.46, 2 cents worse than the analyst estimate of ($0.44).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cowen Lists Top 10 Potential Biotech Surprises Of 2015; Is an Old Fashioned Scandal in the Cards? (GILD) (BIIB) (AEGR) (more...)
- Finish Line (FINL) Misses Q3 EPS by 4c
- Apogee Enterprises (APOG) Misses Q3 EPS by 1c, Revenue Beats, Boosts FY EPS Guidance
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!